MedTrace Logo

Identifying Unique Pathogenic Macrophages in Systemic Sclerosis-ILD

NCT03438032 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2024-11-14

No results posted yet for this study

Summary

Alveolar macrophages isolated from bronchoalveolar lavage (BAL) fluid from systemic sclerosis (SSc) patients with clinically significant lung fibrosis will be studied at baseline and at 6 months after enrollment to assess longitudinally the presence and persistence of an emergent, pro-fibrotic alveolar macrophage population, using single cell RNA-Seq technology to measure the individual transcriptome from each cell.

Conditions

Interventions

DIAGNOSTIC_TEST

Bronchoscopy with lavage

During an elective bronchoscopy procedure, the bronchoscope will be wedged into an affected lung segment guided by CT scanning. When involved an anterior segment will be used to maximize return. After wedging the bronchoscope, 120ml of sterile 0.09% normal saline will be instilled. Up to 40-60 mL of BAL fluid will be obtained for analysis during each sampling.

Sponsors & Collaborators

Principal Investigators

  • Cara Gottardi, PhD · Northwestern University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-06-28
Primary Completion
2022-10-12
Completion
2024-03-08

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03438032 on ClinicalTrials.gov